| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sulfasalazine is primarily known as an anti-inflammatory and disease‐modifying antirheumatic drug (DMARD), used for conditions such as rheumatoid arthritis and inflammatory bowel diseases (e.g., ulcerative colitis). -Inhibit the nuclear factor kappa B (NF-κB) pathway. -Sulfasalazine has been noted to interfere with the cystine/glutamate antiporter (system x_c⁻), which can reduce glutathione levels in cancer cells, potentially making them more susceptible to oxidative stress. -Ability to inhibit anti-oxidant production (for ProOxidant effect).
|
| Source: |
| Type: |
| Differentiation refers to the process by which cells become specialized in structure and function. -In healthy tissues, cells undergo differentiation to become specialized types (e.g., muscle cells, neurons, blood cells) that perform specific functions. This process is tightly regulated by genetic and epigenetic factors. -In some cases, cells can lose their specialized characteristics, a process known as dedifferentiation. This is often seen in cancer, where tumor cells revert to a more primitive, less differentiated state. |
| 5045- | SAS, | Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells |
| - | in-vivo, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:286 Target#:1235 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid